Immunomic Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15010 Broschart Rd Ste 250, Rockville, M...Phone Number
(301) 968-3501Website
www.immunomix.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. is a privately-held clinical stage biotechnology company focused on pioneering nucleic acid immunotherapy platforms, particularly through its proprietary UNiversal Intracellular Targeted Expression (UNITE) technology. The company aims to develop immune-based therapies for oncology, allergies, and animal health, leveraging its innovative approach to create vaccines that elicit broad immune responses. Its pipeline includes investigational products targeting various cancers, including glioblastoma multiforme and Merkel cell carcinoma, currently in different phases of clinical trials. Immunomic Therapeutics is dedicated to improving patient health and extending lives through advanced immunotherapy solutions.Explore more
Immunomic Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunomic Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Immunomic Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Immunomic Therapeutics launches new products
Check out if Immunomic Therapeutics is spiking on competitors!
Check if Immunomic Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Immunomic Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Immunomic Therapeutics has new funding data
Earning: See what the market has to say on Immunomic Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Immunomic Therapeutics
Recommended Actions
Find VP level buyers at Immunomic Therapeutics
Find more new buyers
Compare Similar Companies to Immunomic Therapeutics
Compare insights from companies similar to Immunomic Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunomic Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immunomic Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immunomic Therapeutics.
Immunomic Therapeutics financials insights
Gather financial insights about Immunomic Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Other Financing Round
$600K
2011
Private Equity
$1.6M
2012
Debt
$1.1M
2013
Multiple Rounds
$12.9M
2014
Private Equity
$1M
2017
Debt
$4.6M
2020
Other Financing Round
$61.3M
Debt
$350K
Immunomic Therapeutics Tech Stack
A closer look at the technologies used by Immunomic Therapeutics
Most Recent Scoops
Executive Move
Executive Moves
New Hire
Executive Move
Immunomic Therapeutics has announced that Frances Harrison has joined the organization as Senior VP, Regulatory Affairs.
Left Company
Executive Move
Immunomic Therapeutics has announced that Louise Peltier, Vice President, Regulatory Affair, has retired from the organization.
Facilities Relocation / Expansion
Immunomic Therapeutics is planning to move its offices in April 2023. The move will impact approximately 15 employees at their existing office located at 15010 Broschart Road, Suite #250, Rockville , MD .
Facilities Relocation/Expansion
Open Position
Immunomic Therapeutics News & Media
Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma
ROCKVILLE, Md.--(BUSINESS WIRE)-- #MCC--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced safety and tolerability results from its phase 1 clinical trial evaluating ITI-3000, a plasmid DNA (pDNA) vaccine, targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV).Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme
ROCKVILLE, Md.--(BUSINESS WIRE)-- #cancer--Immunomic Therapeutics, Inc., a privately held, clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced dosing of the first patient in its Phase 1 clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. The study is being conducted at the Dana-Farber Cancer Institute in Boston, MassachusettsHuman DNA Vaccines Market is Expected to Showcase a Significant Growth by 2030 | Pfizer Inc., Immunomic Therapeutics
SEATTLE, WASHINGTON, INDIA, May 16, 2023 /EINPresswire.com/ -- Coherent Market Insights has published a new report on Human DNA Vaccines Market 2023 which includes a detailed analysis based on competitors and important market segments. The global Human …Immunomic Therapeutics Announces Presentation on Manufacturing Cell Therapies at Supply Chain and Logistics for Cell Therapy Summit 2023
ROCKVILLE, Md.--(BUSINESS WIRE)-- #celltherapy--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that it will present at the Supply Chain and Logistics for Cell Therapy Summit, March 7-9 in Boston, MA. Senior Director of External Manufacturing and Supply Chain, Shah Ahmed, will present a talk entitled, “Seamless Cell Therapy Supply: Addressing Bottlenecks, Building C
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Immunomic Therapeutics
Sign Up For FreeTo access detailed company insights
Immunomic Therapeutics, Inc. is a privately-held clinical stage biotechnology company focused on pioneering nucleic acid immunotherapy platforms, particularly through its proprietary UNiversal Intracellular Targeted Expression (UNITE) technology. The company aims to develop immune-based therapies for oncology, allergies, and animal health, leveragi... Read More
